PU23.03 Being a part of the conversation: capacitating youth to participate in HIV prevention conversations using a digital citizen engagement platform in South AfricaPublication OnlyPolicy and advocacy
PU23.04 Lessons learned from the strategic agenda for key populations: Experiences from BrazilPublication OnlyPolicy and advocacy
OA04.03 Distribution of long-acting (LA) cabotegravir (CAB) in plasma, mucosal tissues, and associated fluids after a single ultrasound-guided intramuscular (IM) injection in healthy adult participantsOral Abstract SessionPharmacology/PK and PD studies
OA16.05 A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026)Oral Abstract SessionPharmacology/PK and PD studies
OA19.05LB Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissueOral Abstract SessionPharmacology/PK and PD studies
PE22.02 MRI examination of cabotegravir long-acting formulation depot kinetics in healthy adult volunteersE-posterPharmacology/PK and PD studies
PE22.03 Impact of UGT induction by rifampin and rifabutin on cabotegravir long-acting pharmacokinetics for HIV pre-exposure prophylaxis (PrEP) using population pharmacokinetic modeling and simulationE-posterPharmacology/PK and PD studies
OA08.05LB Development of a novel VRC01-class germline targeting immunogen derived from anti-idiotypic antibodiesOral Abstract SessionNovel vaccine and other prevention approaches
OA09.01 BCG.HTI2auxo.int priming vaccination enhances the HIV-1 specific T cell immune responses elicited by MVA.HTIOral Abstract SessionNovel vaccine and other prevention approaches
OA12.01 Fine-tuning of in vitro transcribed mRNA for optimising a vaccine platform against HIV-1Oral Abstract SessionNovel vaccine and other prevention approaches
seek-warrow-warrow-eseek-e61 - 70 of 444 items